Recall events
/
Event 83908
Event summary
Timeline bucket October 01, 2019
Product types Drug
Classifications Class II
Statuses Completed
Recalling firm wording Dr. Reddy's Laboratories, Inc.
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
18 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 18
Dr. Reddy's: Ranitidine Capsules 150 mg, Rx a.) 60 count bottles (NDC 55111-129-60) b.) 500 count bottles (NDC 55111-129-05)
D-0168-2020
Recall number D-0168-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16350]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 18
Ranitidine Tablets, USP 150 mg, 190 count bottles (2x95) Tray (Sam's Club) OTC, NDC 150062076 UPC Code 078742089720
D-0169-2020
Recall number D-0169-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16501]
FDA event record
· Exact recall-number query on openFDA
drug · product 3 of 18
Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 0363-0010-34), b.) 65 count bottles (NDC 0363-0010-61) , c.) 95 count bottles (NDC 0363-0010-62), d.) 200 count bottles (NDC 0363-0010-01) (Walgreens) OTC
D-0170-2020
Recall number D-0170-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16509]
FDA event record
· Exact recall-number query on openFDA
drug · product 4 of 18
Ranitidine Tablets, USP 150 mg, a.) 65 count bottles (NDC 49035-404-61) b.) 130 count bottles (NDC 49035-404-13) c.) 220 count bottles (NDC 49035-404-65) (Walmart) OTC
D-0171-2020
Recall number D-0171-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16045]
FDA event record
· Exact recall-number query on openFDA
drug · product 5 of 18
Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 30142-505-34), b.) 50 count bottles (NDC 30142-505-50) (Kroger) OTC
D-0172-2020
Recall number D-0172-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16344]
FDA event record
· Exact recall-number query on openFDA
drug · product 6 of 18
Ranitidine Tablets, USP 75 mg, a.) 30 count bottles (NDC 69842-871-30) b.) 80 count bottles (NDC 69842-871-80) c.)160 count bottles (NDC 69842-871-37) (CVS) OTC
D-0173-2020
Recall number D-0173-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16624]
FDA event record
· Exact recall-number query on openFDA
drug · product 7 of 18
Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger)
D-0174-2020
Recall number D-0174-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16480]
FDA event record
· Exact recall-number query on openFDA
drug · product 8 of 18
Ranitidine Tablets 75 mg, a.) 30 count bottles (NDC 63868-482-30), 60 count bottles (NDC 63868-482-60) (CDMA) OTC
D-0175-2020
Recall number D-0175-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16468]
FDA event record
· Exact recall-number query on openFDA
drug · product 9 of 18
Ranitidine Tablets, USP 150 mg, a.) 95 count bottles (NDC 43598-808-62), b.) 220 count bottles (NDC 43598-808-65) (HCA) OTC.
D-0176-2020
Recall number D-0176-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16676]
FDA event record
· Exact recall-number query on openFDA
drug · product 10 of 18
Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 71713-203-02), b.)95 count bottles (NDC 71713-203-05) (Thirty Madison) OTC.
D-0177-2020
Recall number D-0177-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16454]
FDA event record
· Exact recall-number query on openFDA
drug · product 11 of 18
Ranitidine Tablets, USP 75 mg, NDC 57896-715 (GeriCare) OTC.
D-0178-2020
Recall number D-0178-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16446]
FDA event record
· Exact recall-number query on openFDA
drug · product 12 of 18
Ranitidine Tablets, USP 150 mg, 40 count bottles, NDC 11673-849-40 (Target) OTC.
D-0179-2020
Recall number D-0179-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16474]
FDA event record
· Exact recall-number query on openFDA
drug · product 13 of 18
Dr. Reddy's Ranitidine Capsules, USP 300 mg, a.) 30 count bottles (NDC 55111-130-30) b.) 100 count bottles (NDC 55111-130-01)
D-0180-2020
Recall number D-0180-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16355]
FDA event record
· Exact recall-number query on openFDA
drug · product 14 of 18
Dr. Reddy's Ranitidine Tablets, USP 75 mg, 60 count bottles, NDC 55111-131-60, (OTC)
D-0181-2020
Recall number D-0181-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16682]
FDA event record
· Exact recall-number query on openFDA
drug · product 15 of 18
Dr. Reddy's Ranitidine Tablets, USP 150 mg, 24 count bottles, NDC 55111-404-34 (OTC)
D-0182-2020
Recall number D-0182-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16451]
FDA event record
· Exact recall-number query on openFDA
drug · product 16 of 18
Ranitidine Tablets, USP 75 mg, a.) 30- count bottles (NDC 0363-0131-30), b.) 80-count bottles (NDC 0363-0131-80) (Walgreens) OTC
D-0183-2020
Recall number D-0183-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16671]
FDA event record
· Exact recall-number query on openFDA
drug · product 17 of 18
Ranitidine Tablets, USP 150 mg, a.) 24 count bottles (NDC 63868-480-24), b.) 50-count bottles (NDC 63868-480-50) (CDMA) OTC
D-0184-2020
Recall number D-0184-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16487]
FDA event record
· Exact recall-number query on openFDA
drug · product 18 of 18
Ranitidine Tablets, USP 150 mg, NDC 57896-717 (GeriCare) OTC
D-0185-2020
Recall number D-0185-2020
Initiated October 01, 2019
Classification Class II
Status Completed
Quantity N/A
App-derived interpretation
Foreign material or chemical contamination
reason.foreign_material_chemical_contamination · v1.0.0
NDMA impurity
Manufacturing or process control
reason.manufacturing_process_control · v1.0.0
CGMP Deviations
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall CGMP Deviations: Presence of NDMA impurity detected in product.
Code information Batch Numbers: All lots within expiry.
Distribution pattern Product was distributed to major distributors throughout the United States who may have further distributed the product.
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[16494]
FDA event record
· Exact recall-number query on openFDA
